J. Folkman, Addressing tumor blood vessels, Nature Biotechnology, vol.92, issue.6, p.510, 1997.
DOI : 10.1016/S0959-8049(96)00376-0

Y. Takahashi, Y. Kitadai, C. Bucana, K. Cleary, and L. Ellis, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, vol.55, issue.18, pp.3964-3968, 1995.

Y. Takebayashi, S. Aklyama, K. Yamada, S. Akiba, and T. Aikou, Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma, Cancer, vol.92, issue.2, pp.226-231, 1996.
DOI : 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J

R. Radinsky and L. Ellis, Molecular determinants in the biology of liver metastasis, Surg Oncol Clin North Am, vol.5, issue.2, pp.215-229, 1996.

N. Ferrara and T. Davis-smyth, The Biology of Vascular Endothelial Growth Factor, Endocrine Reviews, vol.18, issue.1, pp.4-25, 1997.
DOI : 10.1210/edrv.18.1.0287

A. Gaya and V. Tse, A preclinical and clinical review of aflibercept for the management of cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.484-493, 2012.
DOI : 10.1016/j.ctrv.2011.12.008

C. Sternberg, Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer, Annals of Oncology, vol.19, issue.Supplement 7, pp.91-95, 2008.
DOI : 10.1093/annonc/mdn473

Q. Chu, Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors, Expert Opinion on Biological Therapy, vol.108, issue.2, pp.263-271, 2009.
DOI : 10.1200/JCO.2007.14.7116

A. Lockhart, M. Rothenberg, J. Dupont, W. Cooper, C. P. Sternas et al., Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.28, issue.2, pp.207-214, 2009.
DOI : 10.1200/JCO.2009.22.9237

F. Baffert, T. Le, B. Sennino, G. Thurston, C. Kuo et al., Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling, AJP: Heart and Circulatory Physiology, vol.290, issue.2, 2006.
DOI : 10.1152/ajpheart.00616.2005

A. Eichten, A. Adler, B. Cooper, J. Griffith, Y. Wei et al., Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models, Angiogenesis, vol.79, issue.2, pp.429-441, 2012.
DOI : 10.1007/s10456-012-9328-3

G. Freyer, N. Isambert, B. You, S. Zanetta, C. Falandry et al., Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours, British Journal of Cancer, vol.10, issue.4, pp.598-603, 2012.
DOI : 10.1158/1078-0432.CCR-06-2553

R. Coleman, L. Duska, P. Ramirez, J. Heymach, A. Kamat et al., Phase 1???2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer, The Lancet Oncology, vol.12, issue.12, pp.1109-1117, 2011.
DOI : 10.1016/S1470-2045(11)70244-3

N. Colombo, G. Mangili, S. Mammoliti, M. Kalling, B. Tholander et al., A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites, Gynecologic Oncology, vol.125, issue.1, pp.42-47, 2012.
DOI : 10.1016/j.ygyno.2011.11.021

R. Ramlau, V. Gorbunova, T. Ciuleanu, S. Novello, M. Ozguroglu et al., Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial, Journal of Clinical Oncology, vol.30, issue.29, pp.3640-3647, 2012.
DOI : 10.1200/JCO.2012.42.6932

K. He, B. Cui, G. Li, H. Wang, J. K. Teng et al., The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC), OncoTargets and therapy, vol.5, pp.59-65, 2012.

T. Wang and A. Lockhart, Aflibercept in the treatment of metastatic colorectal cancer, Clin Med Insights, vol.6, pp.19-30, 2012.

E. Van-cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausova et al., Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28, pp.3499-3506, 2012.
DOI : 10.1200/JCO.2012.42.8201

H. Thai, C. Veyrat-follet, N. Vivier, C. Dubruc, G. Sanderink et al., A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects, British Journal of Clinical Pharmacology, vol.37, issue.7, pp.402-414, 2011.
DOI : 10.1111/j.1365-2125.2011.04015.x
URL : https://hal.archives-ouvertes.fr/inserm-00629806

M. Lavielle, MONOLIX (MOdèles NOn LInéaires à effets miXtes), 2008.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005.
DOI : 10.1016/j.csda.2004.07.002

A. Samson, M. Lavielle, and F. Mentre, The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model, Statistics in Medicine, vol.13, issue.27, pp.4860-4875, 2007.
DOI : 10.1002/sim.2950
URL : https://hal.archives-ouvertes.fr/hal-00263511

A. Wald, Tests of statistical hypotheses concerning several parameters when the number of observations is large, Transactions of the American Mathematical Society, vol.54, issue.3, pp.426-482, 1943.
DOI : 10.1090/S0002-9947-1943-0012401-3

K. Brendel, E. Comets, C. Laffont, C. Laveille, and F. Mentre, Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide, Pharmaceutical Research, vol.91, issue.9, pp.2036-2049, 2006.
DOI : 10.1007/s11095-006-9067-5
URL : https://hal.archives-ouvertes.fr/inserm-00189557

E. Comets, K. Brendel, and F. Mentre, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2, pp.154-166, 2008.
DOI : 10.1016/j.cmpb.2007.12.002
URL : https://hal.archives-ouvertes.fr/inserm-00274332

E. Comets, K. Brendel, and F. Mentré, Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics, J Soc Fr Stat, vol.151, pp.106-128, 2010.

R. Savic and M. Karlsson, Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, The AAPS Journal, vol.11, issue.3, pp.558-569, 2009.
DOI : 10.1208/s12248-009-9133-0

D. Mager and W. Jusko, General pharmacokinetic model for drugs exhibiting targetmediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001.
DOI : 10.1023/A:1014414520282

D. Mager, Target-mediated drug disposition and dynamics, Biochemical Pharmacology, vol.72, issue.1, pp.1-10, 2006.
DOI : 10.1016/j.bcp.2005.12.041

D. Mager and W. Krzyzanski, Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition, Pharmaceutical Research, vol.30, issue.10, pp.1589-1596, 2005.
DOI : 10.1007/s11095-005-6650-0

L. Gibiansky, E. Gibiansky, T. Kakkar, and P. Ma, Approximations of the target-mediated drug disposition model and identifiability of model parameters, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.573-591, 2008.
DOI : 10.1007/s10928-008-9102-8

L. Gibiansky and E. Gibiansky, Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD, PAGE, vol.19, 2010.

C. Kut, M. Gabhann, F. Popel, and A. , Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-985, 2007.
DOI : 10.1016/j.canlet.2003.09.018

M. Stefanini, F. Wu, M. Gabhann, F. Popel, and A. , A compartment model of VEGF distribution in blood, healthy and diseased tissues, BMC Systems Biology, vol.2, issue.1, p.77, 2008.
DOI : 10.1186/1752-0509-2-77

J. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum et al., Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.779-786, 2008.
DOI : 10.1007/s00280-007-0664-8

A. Fasanmade, O. Adedokun, J. Ford, D. Hernandez, J. Johanns et al., Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis, European Journal of Clinical Pharmacology, vol.122, issue.4 Suppl 1, pp.1211-1228, 2009.
DOI : 10.1007/s00228-009-0718-4

R. Kerbel and J. Folkman, Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-739, 2002.
DOI : 10.1038/nrc905

J. Li, M. Wientjes, and J. Au, Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery, The AAPS Journal, vol.12, issue.2, pp.223-232, 2010.
DOI : 10.1208/s12248-010-9181-5

H. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag et al., Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303), Journal of Clinical Oncology, vol.28, issue.22, pp.3617-3622, 2010.
DOI : 10.1200/JCO.2010.28.1386

J. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang et al., VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade, Proceedings of the National Academy of Sciences, vol.104, issue.47, pp.18363-18370, 2007.
DOI : 10.1073/pnas.0708865104